Lotus Pharmaceuticals, Inc. (LTUS)
| Market Cap | 11.53M -69.9% |
| Revenue (ttm) | 71.39M +4.3% |
| Net Income | 1.72M -91.6% |
| EPS | 0.06 -92.0% |
| Shares Out | 2.64B |
| PE Ratio | 0.07 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,000 |
| Open | 0.0040 |
| Previous Close | 0.0040 |
| Day's Range | 0.0040 - 0.00436 |
| 52-Week Range | 0.0025 - 0.0111 |
| Beta | -1.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Lotus Pharmaceuticals
Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People’s Republic of China. The company was formerly known as S.E. Asia Trading, Inc. and changed its name to Lotus Pharmaceuticals, Inc. in December 2006. Lotus Pharmaceuticals, Inc. is based in Irvine, California. [Read more]
News
Lenz Therapeutics, Lotus enter license, commercialization agreement for LNZ100
LENZ Therapeutics (LENZ) and Lotus Pharmaceutical (LTUS) announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republi...
Amarin, Lotus Pharmaceuticals partner to commercialize Vazkepa in Southeast Asia
Amarin Corporation (AMRN) and Lotus Pharmaceuticals (LTUS) announced that the two companies have entered into a long-term exclusive partnership to distribute and commercialize VAZKEPA across 10 countr...
Unicycive enters license, development agreement with Lotus in Republic of Korea
Unicycive Therapeutics (UNCY) announced that it has entered into an exclusive license agreement with Lotus Pharmaceutical (LTUS), a leading global pharmaceutical company, for the development and comme...